Bloomberg News (1/14, Edney) reports that “Chelsea Therapeutics International Ltd. won the backing of” an FDA advisory panel “for its drug to prevent sudden drops in blood pressure, a boost for the company’s effort to bring its first product to market.” The piece notes that “many panel members who voted in favor of approval said Chelsea showed the drug works short-term, and that initially is enough for such a rare, devastating disease with no other treatment options.”
Reuters (1/15, Clarke) reports that the drug, Nothera (droxidopa), is for patients with neurogenic orthostatic hypotension (NOH), a rare, chronic type of low blood pressure that is linked with certain neurological disorders such as Parkinson’s disease.
The AP (1/14) and MedPage Today (1/15) also report this story.
No comments:
Post a Comment